CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets

Area of Science:

• Molecular Biology
• Biochemistry
• Cell Biology

Background:

• Cyclin-dependent kinases (CDKs) regulate cell cycle transitions, notably from G1 to S phase, by phosphorylating targets like the Retinoblastoma Protein (Rb).
• Aberrant CDK signaling is a hallmark of cancer, driving uncontrolled cell proliferation.
• The precise mechanisms underlying the differential catalytic efficiencies of CDK complexes remain largely unexplored.

Purpose of the Study:

• To elucidate how CDK4/cyclin-D and CDK2/cyclin-E complexes differentially achieve catalytically competent states for cell cycle progression.
• To investigate the hypothesis that CDK catalytic efficiency, rather than binding specificity, is the primary determinant of cell cycle progression.
• To identify structural and dynamic differences that explain the distinct functional roles of CDK4 and CDK2.

Main Methods:

• Integration of experimental data with computational modeling to establish conformational functional landscapes of active CDK complexes.
• Analysis of dynamic properties within the ATP binding site, regulatory spine, and cyclin interaction interfaces.
• Identification of allosteric regulatory mechanisms, particularly the role of cyclin-D's N-terminus in CDK4 regulation.

Main Results:

• CDK4 exhibits greater dynamics than CDK2 in key functional regions, including the ATP binding site and cyclin interaction interface.
• The N-terminus of cyclin-D allosterically regulates CDK4's activation loop and ATP-binding site.
• CDK4/cyclin-D complexes appear less stable in catalytically competent conformations, suggesting potentially lower catalytic efficiency compared to CDK2/cyclin-E.

Conclusions:

• Differential conformational dynamics and catalytic efficiencies of CDK complexes are critical for precise cell cycle timing.
• The findings suggest catalytic efficiency is a key determinant of cell cycle progression.
• Proposed drug design strategies include allosteric inhibition via conformational stabilization and dynamic entropy-optimized targeting for CDK4.